Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.68 |
| ▸ | PARP1 | P09874 | 5/20 | 0.68 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.68 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.68 |
| ▸ | FYN | P06241 | 1/20 | 0.68 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.56 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.54 |
| ▸ | MST1R | Q04912 | 1/20 | 0.54 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.54 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30560110 | 1.00 | PARP10 (0.68) | PARP10PARP1CLK4DYRK1BFYN | |
| SCHEMBL19187116 | 0.85 | CLK4 (0.74) | PARP10PARP1CLK4DYRK1BFYN | |
| SCHEMBL29985572 | 0.85 | CLK4 (0.74) | PARP10PARP1CLK4DYRK1BFYN | |
| SCHEMBL148819 | 0.84 | PARP10 (0.68) | PARP10PARP1CLK4DYRK1BFYN | |
| Ethane SCHEMBL27832823 | 0.82 | PARP10 (0.66) | PARP10PARP1CLK4DYRK1BFYN | |
| SCHEMBL8264116 | 0.81 | CLK4 (1.00) | PARP10PARP1CLK4DYRK1BFYN | |
| SCHEMBL8737474 | 0.81 | CLK4 (0.52) | PARP10PARP1CLK4DYRK1BFYN | |
| SCHEMBL2619126 | 0.81 | PARP10 (1.00) | PARP10PARP1CLK4DYRK1BFYN | |
| SCHEMBL31585995 | 0.81 | PARP10 (1.00) | PARP10PARP1CLK4DYRK1BFYN | |
| SCHEMBL13090790 | 0.80 | PARP10 (0.49) | PARP10PARP1CLK4DYRK1BFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024112123-A1 | NOVEL COMPOUND AS SELECTIVE ESTROGEN RECEPTOR MODULATOR | 재단법인 대구경북첨단의료산업진흥재단 | 2024-05-30 | — | — | WO | disclosed |
| WO-2024105364-A1 | HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES | CURADEV PHARMA LTD (GB) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024026433-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023158626-A1 | ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| WO-2004083177-A2 | LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004041776-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004037176-A2 | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004031145-A2 | LACTAM-CONTAINING DIAMINOALKYL, BETA-AMINOACIDS, ALPHA-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003047520-A2 | SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048081-A2 | GLYCINAMIDES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003026652-A1 | LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-03 | — | — | WO | disclosed |
| US-5254578-A | Cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1993-10-19 | — | — | US | disclosed |
| EP-0006587-B1 | SULFONYL UREAS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | PARP10 1860/4885PARP1 4034/4885CLK4 385/4885 |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | PARP10 4401/4885PARP1 4690/4885CLK4 1290/4885 |
| US-11857519-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | PARP10 2816/4885PARP1 3218/4885CLK4 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.